Clinical trials: Castration-Resistant Prostate Cancer (CRPC)
Prostate Cancer
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT01083368
- Testing
- temsirolimus, bevacizumab, polymorphism analysis
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer, Castration-resistant Prostate Cancer
Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to describe patterns of care in CRPC patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- TRUMPET (NCT02380274)
- Where
- 148 sites in United States
- Volunteers
- 1,030 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Castration-resistant Prostate Cancer
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.
- Trial name
- NCT06636123
- Testing
- Investigational Agent Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
This study will evaluate if adding the investigational drug Dovitinib to standard androgen ablation therapy (ADT) is beneficial in prolonging the time to disease progression in patients with metastatic prostate cancer who are…
- Trial name
- NCT02065323
- Testing
- Standard ADT, Dovitinib
- Where
- United States
- Sponsor
- Oscar Goodman, Jr.
Bone Metastatic Castration-resistant Prostate Cancer
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
In this study researcher want to gain more information on how the study drug (radium-223) is distributed in the bone, particularly in the tumor free bone in participants with prostate cancer.
- Trial name
- NCT04521361
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 12 sites in Austria, France and 4 more
- Volunteers
- 46 people
- Sponsor
- Bayer
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
To evaluate the safety and efficacy (Overall survival [OS]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.
- Trial name
- NCT01810770
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 27 sites in China, Singapore and 2 more
- Volunteers
- 243 people
- Sponsor
- Bayer
Hormone Refractory Prostate Cancer
Molecular Phenotype Changes and Personalized Treatment for CRPC
To explore the molecular phenotypic changes and personalized treatment in castration-resistant prostate cancer.
- Trial name
- NCT02208583
- Testing
- Docetaxel & Prednisone, DP & Targeted drugs, cisplatin & Etoposide
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Castrate Resistant Prostate Cancer (CRPC)
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
This is a Phase I, non-randomized, multiple-dose, 3+3 dose-escalation study of the safety, pharmacokinetics, biomarkers, preliminary efficacy and patient-reported outcomes of therapeutic vaccine, BPX-101 (formerly BP-GMAX-CD1)…
- Trial name
- NCT00868595
- Testing
- BPX-101, AP1903
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Bellicum Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration resistant prostate cancer (m-CRPC)…
- Trial name
- NCT04060394
- Testing
- Phase I and Phase II: LAE001/prednisone + afuresertib
- Where
- 17 sites in United States, South Korea
- Volunteers
- 49 people
- Sponsor
- Laekna Limited
Prostate Cancer Recurrent
Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer
This is a single-center, randomized, open-label study to assess the feasibility of a low-protein diet intervention in patients with metastatic castrate-resistant prostate cancer (CRPC) who are receiving treatment with…
- Trial name
- NCT03329742
- Testing
- Low protein diet, Control protein diet
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Indiana University
Prostate Cancer
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer.
- Trial name
- NCT01171898
- Testing
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Castrate Resistant Prostate Cancer
Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
The study has three parts. Part 1 is a dose escalation to investigate the safety and tolerability of ASP9521. Part 2 will evaluate the safety and tolerability and initial anti-tumor activity of ASP9521.
- Trial name
- NCT01352208
- Testing
- ASP9521
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Inc
Prostatic Neoplasms
Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects
The primary objectives of this study are to investigate the safety and tolerability of BAY 1841788 in Japanese subjects with metastatic castration-resistant prostate cancer (mCRPC) and the PK of BAY 1841788 and its major…
- Trial name
- NCT02363855
- Testing
- BAY 1841788(ODM-201)
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Bayer
Prostate Cancer
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT00887198
- Testing
- Abiraterone acetate, Prednisone
- Where
- 134 sites in United States, Australia and 9 more
- Volunteers
- 1,088 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants…
- Trial name
- NCT04108208
- Testing
- Apalutamide, Androgen-deprivation Therapy (ADT)
- Where
- 27 sites in China
- Volunteers
- 75 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
This is a Phase Ib, open label study of ARN-509 administered in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT01792687
- Testing
- ARN-509, Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Castration-Resistant Prostate Cancer (CRPC)
Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer
The purpose of this clinical study is to evaluate the safety, tolerability, and efficacy of CP-PCA07 in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT07683013
- Testing
- CP-PCA07, Enzalutamide 40 mg capsule
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Hyundai Bioscience Co., Ltd.
CRPC, Prostate Cancer
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety BIND-014 in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT01812746
- Testing
- BIND-014
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- BIND Therapeutics
Prostate Cancer
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
- Trial name
- NCT00901342
- Testing
- sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 104 people
- Sponsor
- Dendreon